- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04595266
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL)
Randomized, Multicenter Phase II Study of Monoclonal FOLFOX6m + mAb Alone or in Combination With Liver Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease Limited to the Liver With Poor Prognosis
Non-commercial, prospective, randomized, multicenter, national, phase II, open-label comparative clinical trial.
The patients will be randomized in a 1: 1 ratio in two arms:
Control arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab Experimental arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
The main objective is to evaluate the radiological objective response rate according to the RECIST version 1.1 criteria at 6 months. Secondary objectives include: Evaluate overall survival, progression-free survival (PFS), safety profile, hepatic PFS, R0 liver surgery rate.
Study Overview
Status
Intervention / Treatment
Detailed Description
Hepatic intra-arterial therapy (TACE) with irinotecan has been used in several prospective studies demonstrating an acceptable toxicity profile. Two randomized phase II studies have evaluated the efficacy of TACE with irinotecan compared to conventional chemotherapy in metastatic colon cancer. A second-line treatment study demonstrated an increase in PFS in the TACE versus FOLFIRI treatment arm.
A prospective open, randomized, multicenter phase II study is proposed that will include patients with liver metastases of colorectal origin with poor prognostic criteria.
LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. The device uses 100 +/- 50 micron microspheres of hydrogel into which chemotherapeutic agents are loaded and delivered into the hepatic artery to treat liver tumors. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
Systemic treatment will be administered according to the usual guidelines:
-FOLFOX6m for 6 months + monoclonal Ab (cycles are repeated every 15 days) Premedication: Dexamethasone 20 mg IV + ondansetron 8mg IV
The dose of FOLFOX will be:
Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.
Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1. In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.
In the combination arm of systemic chemotherapy with IRINOPEARL, in the 2nd and 4th cycles, chemotherapy will be replaced by treatment with hepatic chemoembolization with IRINOPEARL.
The disease will be evaluated by CT or MRI at baseline and every 12 weeks until progression according to RECIST 1.1 criteria.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Federico Nepote
- Phone Number: 934344412
- Email: investigacion@mfar.net
Study Contact Backup
- Name: Verónica Roca
- Phone Number: 934344412
- Email: investigacion@mfar.net
Study Locations
-
-
-
Alicante, Spain
- Recruiting
- Hospital Universitario de Alicante
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
Barcelona, Spain
- Recruiting
- Hospital Clinic
-
Contact:
- Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
Principal Investigator:
- Investigator Selected by Sponsor
-
Barcelona, Spain
- Recruiting
- Hospital de la Santa Creu i Sant Pau
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
Madrid, Spain
- Recruiting
- Hospital Universitario 12 de Octubre
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
Madrid, Spain
- Not yet recruiting
- Hospital Universitario La Paz
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
Pamplona, Spain
- Recruiting
- Complejo Hospitalario de Navarra
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
Tenerife, Spain
- Recruiting
- Hospital Universitario de Canarias
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
Valencia, Spain, 46026
- Recruiting
- Hospital Universitari i Politecnic La Fe
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
-
Barcelona
-
Sabadell, Barcelona, Spain
- Recruiting
- Hospital Parc Taulí
-
Principal Investigator:
- Principal Investigator Selected by Sponsor
-
Contact:
- Principal Investigator Selected by Sponsor
- Email: investigacion@mfar.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged ≥ 18 years.
- Patients with colorectal cancer and exclusive liver metastases with poor prognostic criteria,> 3 lesions and / or size> 5 cm. Patients with a diagnosis of liver metastases with synchronous presentation or with a disease-free interval may be included. If the primary tumor has not been resected, it must be clinically stable.
- Measurable disease following RECIST version 1.1 criteria
Adequate bone marrow function, according to:
- Hemoglobin ≥ 9.0 g / dl (patients with hemoglobin <9 g / dl can be transfused before inclusion in the study
- Platelet count ≥ 100 x 109 / L
- Absolute Neutrophil Count (ANC) ≥ 1.5x 109 / L
Adequate liver function, according to:
- Serum bilirubin ≤ 1.5 x the upper limit of normal (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.
- Alkaline phosphatase ≤ 5 x ULN or ≤10 x ULN in the presence of bone metastases
- Adequate renal function, with creatinine levels <1.5 mg / dL. Blood Ureic Nitrogen (BUN)> 50 ml / min.
- Albumin> 3.0 g / dL
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
- Patients capable of understanding the information and giving their written informed consent to participate in the study
- Women of childbearing potential must commit to sexual abstinence or use of barrier contraceptive methods during the study and must have a negative pregnancy test.
Exclusion Criteria:
- Extension of the disease> 50% of the liver parenchyma (evaluated by CT performed within the month prior to inclusion)
- Previous chemotherapy treatment for metastatic colorectal cancer
- Clinically significant cardiovascular diseases: cerebrovascular accident / stroke (≤ 6 months before inclusion in the trial), myocardial infarction (≤ 6 months before inclusion in the trial), unstable angina, uncontrolled hypertension, congestive heart failure of New York Heart Association (NYHA) grade II or higher or severe cardiac arrhythmia.
- History of malignancy in the last three years, except for basal cell carcinoma of the skin or carcinoma in situ of the cervix treated appropriately.
- Altered coagulation (Quick> 50%)
- Patients with active infectious processes
- Patients with any of the contraindications specified in the technical data sheet of the study drug or with allergies to some of the drugs used
- Pregnant or lactating patients
- Portal thrombosis
- Severe portal hypertension
- Extrahepatic metastases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab).
|
Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle. Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1
Other Names:
In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m. Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications.
Other Names:
|
Experimental: Experimental
Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
|
Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle. Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1
Other Names:
In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m. Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications.
Other Names:
Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres.
Irinotecan will be loaded at a dose of 100 mg.
LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization.
This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis.
The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Evaluated at 6 months after first investigation drug administration.
|
The proportion of patients with tumor size reduction according to RECIST 1.1 criteria at 6 months
|
Evaluated at 6 months after first investigation drug administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Through study completion, average 2 years
|
Time from randomization until death from any cause.
Patients still alive at the last contact or lost to follow-up will be censored.
|
Through study completion, average 2 years
|
Progression free survival
Time Frame: Through study completion, average 2 years. Evaluated during a total of 2 years (estimated) by CT scan or MR every 12 weeks
|
Time from from the date of randomization to the date of first documented disease progression according to RECIST 1.1 criteria or the date of death due to any cause.
Patients without radiological documentation of progression will be censored on the date of the last control without evidence of progression.
|
Through study completion, average 2 years. Evaluated during a total of 2 years (estimated) by CT scan or MR every 12 weeks
|
Frequency of adverse events
Time Frame: Through study completion, average 2 years
|
Percentage of adverse events, laboratory alterations and treatment discontinuations observed in both treatment arms classified by type and severity (Safety)
|
Through study completion, average 2 years
|
Hepatic Progression free survival
Time Frame: Through study completion, average 2 years. Evaluated during a total of 2 years (estimated) by CT scan or MR every 12 weeks
|
Time from from the date of randomization to the date of first documented disease progression within the liver according to RECIST 1.1 criteria or the date of death due to any cause.
Patients without radiological documentation of progression will be censored on the date of the last control without evidence of progression.
|
Through study completion, average 2 years. Evaluated during a total of 2 years (estimated) by CT scan or MR every 12 weeks
|
Proportion of patients with liver surgery
Time Frame: Through study completion, average 2 years.
|
Proportion of patients undergoing R0 surgery for liver metastases
|
Through study completion, average 2 years.
|
Collaborators and Investigators
Investigators
- Study Chair: Estela Pineda, M.D, Hospital Clinic of Barcelona
- Study Chair: David Páez, M.D., Ph.D., Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Oxaliplatin
- Bevacizumab
- Leucovorin
- Irinotecan
Other Study ID Numbers
- GEMCAD-1802
- 2020-003795-40 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer Metastatic
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on FOLFOX regimen
-
Fox Chase Cancer CenterRecruiting
-
Biotheus Inc.RecruitingHepatocellular CarcinomaChina
-
Tang-Du HospitalRecruiting
-
Jiangsu Province Hospital of Traditional Chinese...UnknownPeripheral NeuropathyChina
-
Ohio State UniversityOsato Research InstituteCompleted
-
AmgenCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingColorectal Cancer | Chemotherapy Effect | Liver Metastases | Circulating Tumor CellChina
-
Stanford UniversityActive, not recruitingRectal CancerUnited States
-
Federation Francophone de Cancerologie DigestiveRoche Pharma AGCompleted
-
WntResearch ABInstitut Català d'Oncologia; SMS-Oncology BV; SAGA diagnostics AB; Unilabs A/S; BioVica...Active, not recruiting